Vascular Supply Identification, Lesion Extension and Search for Tumor Similarity at a Distance by VTM in Breast Cancer
- Disease/Condition
- Breast Cancer Female
- Drug/Device/Intervention
- VTM examination and breast biopsy
- Study type
- Interventional
- Intervention type
- device
- Primary sponsor
- Galzu Institute of Research, Teaching, Science and Applied Technology
- Phase
- N/A
- Start date
- Oct 01, 2023
- End date
- May 01, 2024
- Enrollment
- 120 participants
Concordance of the diagnosis of abnormality during the VTM exam in relation to the standard exam (mammography);,Frequency of non-visible vascular identification:,Frequency of identifying non-visible textures,Frequency of thermal discrepancy in nearby pixels in areas suspected of non-visible abnormalities:,Frequency of sample changes detected by VTM
When we talk about early identification, we are talking about an ALREADY EXISTING INJURY,
 triggering a change in the patient's quality of life and a projection of future costs for the
 health system.
 
 INNOVATIVE ASPECT: While screening mammography identifies an existing lesion, VTM could: Make
 an early diagnosis before the formation of a visible or palpable tumor mass; Check the
 metabolic activity in suspicious lesions identified by other diagnostic methods; Demarcate
 tumor range and tumor similarity from a distance in breast cancer.
 
 Regarding the Risk x Benefit:There are no medications incorporated, associated or
 administered by the equipment; There is no ionizing radiation incorporated or delivered by
 the equipment; There are no contraindications for the use of the equipment by the patient
 (Non-ionizing infrared radiation, without contrast or contact); Audience destined to operate
 the equipment: Physician / Radiologist with training Therefore, the research in question is
 of great relevance for such a debilitating health problem for the patient and for the health
 system.
- Registry
- ClinicalTrials.gov
- Trial ID
- NCT06045572
- Type
- Device Trial
Access comprehensive clinical trial information for NCT06045572 through Pure Global AI's free database. This phase not specified trial is sponsored by Galzu Institute of Research, Teaching, Science and Applied Technology and is currently Not yet recruiting. The study focuses on Breast Cancer Female. Target enrollment is 120 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.